Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
As the FTSE indices reel from weak Chinese trade data, a screen of undervalued UK equities reveals potential opportunities. We examine three companies trading significantly below their estimated cash flow value.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
A quirk in the UK tax system means those earning between £100,000 and £125,140 face an effective 60% marginal tax rate, while also losing crucial childcare benefits. We examine the growing trap and the financial planning strategies to navigate it.
Chinese regulators have conditionally approved leading AI startup DeepSeek to purchase Nvidia's advanced H200 artificial intelligence chips, sources tell Reuters, as Beijing navigates competing pressures to advance its tech sector while managing geopolitical tensions.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
Apple is reportedly planning to prioritize the launch of its three highest-tier iPhone models in 2026, while delaying the rollout of a new standard edition, according to a Nikkei Asia report citing sources familiar with the matter. The move signals a strategic pivot towards the premium segment amid ongoing supply chain considerations.
As trillion-dollar AI infrastructure spending fuels concerns of a market bubble, long-term investors are questioning whether broad index funds like the Vanguard S&P 500 ETF still offer a safe harbor.
In a major policy shift, the CFTC under new Chairman Michael Selig is drafting a comprehensive rulebook for event contracts, aiming to bring regulatory certainty to the fast-growing prediction market industry while fostering 'permissionless innovation.'
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
The IT infrastructure giant is deepening its SAP partnership with a new Center of Excellence and an AI-powered 'Clean Field' methodology, aiming to automate complex migrations and modernizations for enterprise clients. The strategic push highlights Kyndryl's attempt to pivot from low-margin maintenance work to higher-value AI-enabled transformation services.
Despite a softer-than-expected first quarter, Beazer Homes USA outlines a dual strategy of solar-powered community expansion and aggressive capital returns to shareholders, aiming to boost profitability in a stabilizing housing market.
Archer Aviation has inked a strategic partnership with Serbia to supply its electric air taxis, positioning the company as the official urban air mobility partner for the 2027 Belgrade Expo. The agreement marks a significant expansion into Europe and includes options for fleet sales and local industrial collaboration.
Visa Inc. reported a 15% surge in net revenue for its first fiscal quarter of 2026, citing robust payments volume and significant gains in its value-added services and commercial solutions.
Amidst global market turbulence, a new screen reveals a significant number of Asian stocks are trading below their intrinsic value, with discounts as high as 26.4%. We examine three standout companies from South Korea, Thailand, and Japan that appear poised for a potential re-rating.
Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.
Proposed flat payment rates for 2027 by CMS intensify margin pressures on Medicare Advantage insurers like Clover Health, raising investor concerns about cost management and growth prospects in a tightening regulatory landscape.
Kirby Corporation (NYSE: KEX) reported record annual earnings for 2025, fueled by robust free cash flow and strategic capital returns. While Q4 faced seasonal pressures, management highlighted a late-quarter rebound in inland marine and surging demand in power generation, setting the stage for what they project as a year of steady financial performance in 2026.
